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Abstract
We report on the analysis of endogenous peptides in cerebrospinal fluid (CSF) by mass spectrometry. A method was
developed for preparation of peptide extracts from CSF. Analysis of the extracts by offline LC-MALDI MS resulted in the
detection of 3,000–4,000 peptide-like features. Out of these, 730 peptides were identified by MS/MS. The majority of these
peptides have not been previously reported in CSF. The identified peptides were found to originate from 104 proteins, of
which several have been reported to be involved in different disorders of the central nervous system. These results support
the notion that CSF peptidomics may be viable complement to proteomics in the search of biomarkers of CNS disorders.
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Introduction
For diseases of the central nervous system (CNS), cerebrospinal
fluid (CSF) is a valuable source of biomarkers that can aid in
diagnosis, provide clues to disease mechanisms and facilitate
development of novel therapies. Generated through filtration of
blood in the choroid plexus and by diffusion from the extracellular
matrix of the brain into the ventricles [1], the CSF surrounds the
brain and the spinal cord. Being in direct contact with the brain,
many brain proteins diffuse into the CSF; approximately 20% of
the proteins in CSF are estimated to be brain-derived [2]. CSF is
produced at a rate of 500 ml/day and turns over approximately 4
times per day by drainage into the blood [3]. Thus, many ongoing
processes in the CNS are reflected in the molecular composition of
the CSF. Several CSF biomarkers have already been identified for
various diseases and are used in research, clinical trials and clinical
practice, including CSF-specific IgG immunoglobulins in multiple
sclerosis, the 14-3-3 protein in Creutzfeld-Jakob’s disease (CJD),
the tau protein, and the b-amyloid peptides in Alzheimer’s disease
(AD).
While several proteomic studies have expanded our knowledge
of the CSF protein composition [1,4–14], there are comparatively
few reports on the CSF peptidome. A few recent studies have
identified a large number of endogenous peptides in the CSF [14–
17]. Several truncated forms of these peptides and the proteins
they derive from are involved in diverse biological processes, e.g.,
degeneration/regeneration, neuronal damage, growth, develop-
ment, and learning [2]. Others may reflect the proteolytic activity
in the CNS that leads to their formation through metabolic
processing [16]. Studies have shown that peptide patterns can
discriminate between different forms of cancer in serum [18–20]
and discriminate AD patients from controls in both serum and
CSF [21,22].
Compared to CSF proteomics, the pursuit of the CSF
peptidome is also motivated for analytical reasons. The CSF
protein composition spans a concentration range of over ten
orders of magnitude and is dominated by a small number of highly
abundant proteins, most notably albumin, which accounts for over
60% of the total protein content [23–25]. Compared to albumin,
for example, the concentration of the tau protein, a marker of
neuronal degradation, is a million-fold lower. Global proteomic
workflows generally have a strong bias towards detecting proteins
of high abundance. The reasons for this are both the dynamic
range of the mass spectrometric instrumentation, as well as the
limited loading capacity of the separation techniques used
upstream of the mass spectrometer. This requires the use of
extensive sample prefractionation and sample enrichment for the
detection and identification of low abundant proteins. The
complexity of such workflows results in long analysis times and
often compromises the analytical reproducibility, thereby ham-
pering their use in clinical proteomic studies, in which compar-
ative analysis of large sample sets are required. The peptides in
CSF, in contrast, can be isolated relatively easily. Yuan et al
demonstrated that ultrafiltration is an effective method for
isolating the low molecular weight fraction (,5 kDa) of the
human lumbar CSF proteome [17]. Using this strategy, Zougman
et al analyzed the CSF peptidome and proteome in depth, and
found 563 endogenous peptides originating from 91 proteins [14].
Here we employed nano-LC coupled to off-line to matrix-
assisted laser desorption/ionization (MALDI) MS for analyzing
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CSF peptides in the mass range 700–5,000 Da. A method based
on ultrafiltration for preparation of peptide extracts from CSF was
optimized. This workflow is aimed to be suitable for comparative
analysis of large clinical sample sets, necessitating a fast and simple
sample preparation.
Results and Discussion
Sample preparation
The CSF peptidome constitutes only a minor fraction of the
total protein contents of CSF. Several known bioactive peptides
are present at concentrations in the pg/ml range, requiring the
analysis of a few hundred microlitres of CSF to detect them by
mass spectrometry. Because of the limited loading capacity of
nano-LC columns (,1 mg), it is necessary to enrich the peptide
fraction. Ultrafiltration using molecular weight cut-off (MWCO)
filters provides a simple means to achieve this. Filters of different
cut-off sizes (10 kDa, 30 kDa, 50 kDa) were evaluated. 50 kDa
filters resulted in permeability of significant amounts of albumin
(data not shown). While 10 kDa filters efficiently removed
albumin, they retained a large part of the peptides in the mass
range of interest (data not shown). According to the product
documentation for the filters the recovery of a peptide of 1,350 Da
is only approximately 76%. 30 kDa filters were found optimal for
our application, achieving efficient removal of albumin, the most
abundant CSF protein, without compromising peptide recovery.
From studies in plasma and CSF it is well known that many
peptides bind to larger proteins and may therefore be retained in
the ultrafiltration step [15,26–28]. To improve the recovery of
such peptides we investigated the effect of pretreating CSF samples
with different concentrations of acetonitrile (ACN) and formic acid
(FA), in order to dissociate the peptides from the carrier proteins
prior to the ultrafiltration step. A CSF pool was divided into
several 500 ml aliquots to which ACN or FA were added at
different concentrations as described in the method section. The
filtrates were analyzed by LC-MALDI MS and evaluated on the
basis of number of detected compounds. Without any sample
pretreatment, 2,445 compounds were detected (Figure 1 a). In a
CSF sample treated with 20% ACN, the number of detected
compounds increased to 3,543 (Figure 1 b). When the concentra-
tion of ACN was increased to 40% the amount of peptides in the
flow through dropped significantly. A possible explanation for the
observed decrease is that at this high ACN concentration, a large
part of the sample proteins precipitate, resulting in co-precipitation
of peptides. The highest numbers of compounds were detected
when the CSF was incubated with 20% ACN. Addition of FA up
to 5% to the samples also increased the number of detected
compounds, however less than ACN. Increasing the FA concen-
tration to 10% did not yield any additional improvement.
Combining ACN and FA yielded poor results.
Peptide identification
Identification of endogenous peptides by sequence database
searching is more challenging than identification of proteins in
tryptic digests. Because the peptides are not produced by cleavage
by one specific protease, restrictions regarding enzyme cleavage
specificity cannot be applied in the database search, increasing the
number of peptide sequences to consider in the search by a factor
of 100–1,000, and thereby decreasing the significance of the
matches in the database searches. Performing a database search
with Mascot and filtering for a false discovery rate (FDR) of 1%
(corresponding to a Mascot MOWSE score of 41 in the search)
resulted in 596 peptide identifications. However, upon inspection
of peptide hits with lower scores it was found that several of these
could be confirmed based on the characteristic fragment ions
arising from the presence of specific amino acids and the location
of charged residues in the amino acid sequence. For singly charged
peptide ions, strong charge-remote fragmentation C-terminally to
aspartic acid and, to somewhat lesser degree, glutamic acid for
peptides containing arginine, produces characteristic b- or y-
fragment ions, depending on the location of the arginine [29,30].
Prominent cleavage N-terminally to proline residues also produces
strong b- or y- ions. Peptides that display these fragmentation
characteristics often score poorly in database searches due to their
selective fragmentation. However, these diagnostic fragment ions
provide means to manually evaluate peptide specific matches
retrieved by database searches.
For peptide identification, manual validation was performed on
all database search results retrieved using a relatively low score
threshold: ion score .15 and at least one peptide per protein with
ion score .27. With these settings, a total of 4,185 peptide
matches were retrieved. Manual validation was based primarily on
the fragmentation rules discussed above for peptides containing
aspartic acid/glutamic acid and arginine, and peptides containing
proline. Upon inspection of the raw spectra, errors in the
automatic peak detection were corrected, sometimes increasing
the number of assigned peaks. In some cases validation was
supported by similarity of the fragment ion pattern with that of an
already identified peptide, covering partly the same amino acid
sequence.
Figure 2 shows two examples illustrating the application of the
described validation criteria for a strong and a weak peptide
match. The fragment ion spectrum of m/z 3511.7738 (Figure 2 a)
matched the peptide SVNPYLQGQRLDNVVAKKSVPHFS-
DEDKDPE from Neuroendrocrine protein 7B2 with an ion score
of 194.9. Charge-remote fragmentation C-terminally to Asp-12,
Asp-25, Asp-27, and Asp-29 due to the presence of arginine at the
N-terminal part of the peptide (Arg-10) results in abundant
corresponding b-ions, confirming the assignement of the peptide.
The lowest scoring peptide match which was validated was the
peptide KANDESNEHSDVIDSQELSKVSREFH (m/z
3000.3891) derived from Osteopontin, which received an ion
score of 15.8. Prominent charge-remote fragmentation is observed
C-terminally to Asp-14, Asp-11, Glu-8 (y-18), Glu-17 (y-9), in this
case giving rise to the corresponding strong y-ions, y12, y15, y18,
and y9, respectively, due to the presence of Arg-23 near the C-
terminus of the peptide. Despite that the spectrum in the latter
example only contains a few fragment ion signals the predictability
of the fragment ion peak pattern based on the matched peptide
sequence provides evidence for the correctness of the identifica-
tion.
A histogram of the number of manually validated and rejected
peptide matches as a function of ion score (Figure 3) shows that
quite a large number of peptide hits with low ion score could be
validated. A total of 730 peptide matches were validated. The 22%
increase of assigned peptides by manual evaluation compared to
the 596 peptides identified with an FDR of 1% in the Mascot
database search is significant and suggests that, particularly for the
analysis of singly-charged ions, search algorithms may be
improved by implementing amino acid- and charge-based
fragmentation schemes in their scoring algorithms.
The identified peptides are listed in Table S1. The identifica-
tions comprised 626 unique peptide sequences (not taking into
account post-translational modifications) originating from 104
proteins (Table 1). The mass spectrometric data is available via the
PRoteomics IDEntifications database [31] (PRIDE, http://www.
ebi.ac.uk/pride/, Accession number 24353).
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Figure 1. LC-MS profiles of CSF peptides. The LC retention time is shown on the y-axis and the m/z on the x-axis. (a) Without sample
pretreatment, 2,445 compounds were detected. (b) When adding 20% ACN prior to the ultrafiltration step, the number increased to 3,543.
doi:10.1371/journal.pone.0042555.g001
Figure 2. Peptide identification. (a) MS/MS spectrum of an ion of m/z 3511.7738 matching the peptide SVNPYLQGQRLDNVVAKKSVPHFSDEDKDPE
from Neuroendrocrine protein 7B2 with an ion score of 192.4. Charge-remote fragmentation C-terminally to Asp-12, Asp-25, Asp-27, and Asp-29 due
to the prescence of arginine at the N-terminal part of the peptide (Arg-10), results strong corresponding b-ions. (b) MS/MS spectrum of an ion of m/z
3000.3891 matching the peptide KANDESNEHSDVIDSQELSKVSREFH with an ion score of 15.8. Charge-remote fragmentation is observed C-terminally
to Asp-14, Asp-11, Glu-8 (y-18), Glu-17 (y-9), in this case giving rise to the corresponding strong y-ions, y12, y15, y18, and y9, respectively, due to the
presence of Arg-23 near the C-terminus of the peptide.
doi:10.1371/journal.pone.0042555.g002
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Comparisons with other studies
Comparing the peptides identified in our study to those
identified in the study by Zougman et al. [14], one of the most
comprehensive CSF peptidomic studies to date, showed that only
23% of the peptides identified in our study were present in the
other data set (Figure 4 a). The large difference between the data
sets may be attributed to the different ionization techniques used
in the two studies (MALDI vs. ESI), to differences in the method
used for preparation of the peptide extracts, and that different CSF
samples were analyzed.
To assess how the CSF peptidome compares to the CSF
proteome, we compared the proteins represented by the endog-
enous peptides identified in the current study and in the study by
Zougman et al. with the extensive CSF proteomic analysis by
Schutzer et al. comprising 2,462 proteins [7] (Figure 4 b). Both
peptidomic data sets have high overlap with the proteomic set.
Thus, on a protein level, the peptidomic approaches used in the
two studies mainly identifies peptides derived from the same
proteins that are found by global proteomic analyses.
Biological functions of the identified proteins
While the significance of the endogenous peptides in CSF is still
largely unknown, several of the precursor proteins from which
they derive are associated with various brain disorders and known
cellular processes in the brain. A few examples are given below.
While the presence in CSF of all of these proteins has been
reported previously [7], several of the endogenous peptides
derived from these proteins are reported for the first time.
Amyloid beta peptides. The amyloid beta A4 protein
(amyloid precursor protein, APP) plays a central role in the
pathophysiological processes in AD, which is characterized by
progrediating neuronal degeneration with amyloid deposits [32].
By enzymatic processing of APP, the peptide amyloid beta (Ab) 1–
42 is generated which is highly prone to aggregation and is the
major constituent of the amyloid plaques that form in the brain.
Ab1–42 is also used as a CSF biomarker for AD [33]. In this study,
we detected Ab1–14, 1–15, 1–16, 1–17, 1–19, and 5–15 (Figure 5
a). The existence of several of these fragments have been recently
reported in CSF in a study using immunoprecipitation in
combination with mass spectrometry [34]. The C-termini of these
fragments span the a-secretase cleavage site and may thus be
markers of non amyloidogenic APP processing that may be
protective from AD [35]. The identification of Ab5–15 is the first
report of this truncated form in CSF. The identification of Ab
peptides starting at position 5 is especially interesting since such
peptides may represent the activity of an APP processing pathway
that is up-regulated after inhibition of the major Ab producing
enzyme BACE1 [36,37] and CSF Ab5-X peptides may be useful
as pharmacodynamic markers in trials of BACE1-inhibitors [38].
APLP1. CSF also contains several amyloid-like proteins,
which have sequence homology to APP, and that to some extent
undergo similar processing. One such protein is the amyloid
precursor-like protein 1 (APLP1). APLP1 undergoes processing by
BACE and c-secretase generating Ab-like peptides of which one
has been shown to have potential value as a biomarker for AD
[39]. Several of these Ab-like peptides were also identified in our
Figure 3. Stacked histogram of all peptide matches as a function of ion score. Peptide matches were retrieved that fulfilled the criteria: ion
score .15 and at least one peptide match with ion score .27 per protein. The coloured segments indicate the number of validated (green) and
rejected (red) peptide matches.
doi:10.1371/journal.pone.0042555.g003
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Table 1. List of identified proteins from the analysis of the CSF peptidome using LC-MALDI MS/MS.
Entry name Protein name
PTPRR_HUMAN Receptor-type tyrosine-protein phosphatase R isoform 1 precursor
NBL1_HUMAN Neuroblastoma suppressor of tumorigenicity 1 isoform 1
PLM_HUMAN Phospholemman precursor
CADH2_HUMAN Cadherin-2 preproprotein
THRB_HUMAN Prothrombin preproprotein
A4_HUMAN Amyloid beta A4 protein isoform h precursor
ADML_HUMAN ADM precursor
TICN3_HUMAN Testican-3 isoform 1
VTNC_HUMAN Vitronectin precursor
CXL16_HUMAN C-X-C motif chemokine 16
7B2_HUMAN Neuroendocrine protein 7B2 isoform 2
OSTP_HUMAN Osteopontin-D
CSTN1_HUMAN Calsyntenin-1 isoform 2
TTHY_HUMAN Transthyretin precursor
SODC_HUMAN Superoxide dismutase [Cu-Zn]
SORC2_HUMAN VPS10 domain-containing receptor SorCS2 precursor
CD99_HUMAN CD99 typeII
FIBB_HUMAN Fibrinogen beta chain isoform 1 preproprotein
CO3_HUMAN Complement C3 precursor
TYB10_HUMAN Thymosin beta-10
FIBG_HUMAN Fibrinogen gamma chain isoform gamma-A precursor
PGCB_HUMAN Brevican core protein isoform 1
SAA3_HUMAN Putative serum amyloid A-3 protein
APLP2_HUMAN Amyloid-like protein 2 isoform 4 precursor
TENR_HUMAN Isoform 2 of Tenascin-R
AACT_HUMAN Isoform 3 of Alpha-1-antichymotrypsin
FXYD6_HUMAN FXYD domain-containing ion transport regulator 6 precursor
SCG1_HUMAN Secretogranin-1 precursor
COIA1_HUMAN Isoform 3 of Collagen alpha-1(XVIII) chain
ANGL2_HUMAN Angiopoietin-related protein 2 precursor
DKK3_HUMAN Dickkopf-related protein 3 precursor
C99L2_HUMAN CD99 antigen-like protein 2 isoform 3 precursor
CAD19_HUMAN Cadherin-19 preproprotein
FBLN3_HUMAN Isoform 4 of EGF-containing fibulin-like extracellular matrix protein 1
SE6L1_HUMAN Seizure 6-like protein isoform 2 precursor
ANFC_HUMAN C-type natriuretic peptide precursor
AUGN_HUMAN Augurin precursor
NPTXR_HUMAN Neuronal pentraxin receptor
TRH_HUMAN Prothyroliberin precursor
PCSK1_HUMAN ProSAAS precursor
SFRP4_HUMAN Secreted frizzled-related protein 4 precursor
ITIH5_HUMAN LLLL311
FMOD_HUMAN Fibromodulin precursor
MIME_HUMAN Mimecan preproprotein
SPRL1_HUMAN SPARC-like protein 1 precursor
ECM1_HUMAN Extracellular matrix protein 1 isoform 3 precursor
CART_HUMAN Cocaine- and amphetamine-regulated transcript protein
APOE_HUMAN Apolipoprotein E precursor
NSG1_HUMAN Neuron-specific protein family member 1
CSF Peptidomics by LC-MALDI MS
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Table 1. Cont.
Entry name Protein name
PRIO_HUMAN Isoform 2 of Major prion protein
GELS_HUMAN Gelsolin isoform a precursor
PTGDS_HUMAN Prostaglandin-H2 D-isomerase
PTPRZ_HUMAN Isoform Short of Receptor-type tyrosine-protein phosphatase zeta
A2AP_HUMAN Alpha-2-antiplasmin isoform a precursor
P3IP1_HUMAN HGFL(S) protein
CADM3_HUMAN Isoform 3 of Cell adhesion molecule 3
SCG2_HUMAN Secretogranin-2 precursor
IBP5_HUMAN Insulin-like growth factor-binding protein 5 precursor
A1ATR_HUMAN Putative alpha-1-antitrypsin-related protein
GP158_HUMAN Probable G-protein coupled receptor 158 precursor
SCG3_HUMAN Secretogranin-3 isoform 1 precursor
FIBA_HUMAN Fibrinogen alpha chain isoform alpha preproprotein
GPR37_HUMAN Probable G-protein coupled receptor 37 precursor
CSF1_HUMAN Macrophage colony-stimulating factor 1
TICN1_HUMAN Testican-1 precursor
SFRP3_HUMAN Secreted frizzled-related protein 3 precursor
CMGA_HUMAN Chromogranin-A preproprotein
NCKX2_HUMAN Sodium/potassium/calcium exchanger 2 isoform 2
ITA7_HUMAN Isoform Alpha-7X2DB of Integrin alpha-7
RNAS1_HUMAN Ribonuclease pancreatic precursor
A1AT_HUMAN Isoform 3 of Alpha-1-antitrypsin
PENK_HUMAN Proenkephalin-A preproprotein
SMS_HUMAN Somatostatin preproprotein
CO4A_HUMAN Complement C4-A
IGF2_HUMAN Isoform 2 of Insulin-like growth factor II
APLP1_HUMAN Amyloid-like protein 1 isoform 1 precursor
PTPR2_HUMAN Isoform 3 of Receptor-type tyrosine-protein phosphatase N2
TKNK_HUMAN Tachykinin-3 isoform 2 preproprotein
MOG_HUMAN Isoform 9 of Myelin-oligodendrocyte glycoprotein
CYTC_HUMAN Cystatin-C precursor
CLUS_HUMAN Isoform 5 of Clusterin
PCDG3_HUMAN Protocadherin gamma-A3 isoform 1 precursor
XYLT1_HUMAN Xylosyltransferase 1
ETBR2_HUMAN Endothelin B receptor-like protein 2 precursor
CSF1R_HUMAN Macrophage colony-stimulating factor 1 receptor precursor
PNOC_HUMAN Prepronociceptin preproprotein
SPRC_HUMAN SPARC precursor
SORT_HUMAN Sortilin isoform 1 preproprotein
ITM2B_HUMAN Integral membrane protein 2B
TYB4_HUMAN Thymosin beta-4
NCAM1_HUMAN Neural cell adhesion molecule 1 isoform 4 precursor
SYT11_HUMAN Synaptotagmin-11
SELPL_HUMAN P-selectin glycoprotein ligand 1 isoform 2
PRR24_HUMAN Proline-rich protein 24
VGF_HUMAN Neurosecretory protein VGF precursor
MGP_HUMAN Matrix Gla protein isoform 2 precursor
CSTN3_HUMAN Calsyntenin-3 precursor
HPT_HUMAN Haptoglobin isoform 1 preproprotein
CSF Peptidomics by LC-MALDI MS
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study, four of which have N-termini at the BACE cleavage site
(Arg-167) in APLP1 (Figure 5 b). The peptides derived from
APLP1 and APP may thus be used in parallel in clinical studies to
monitor the activity of these secretases to investigate if similar
patterns of peptides are affected in different disease or to monitor
effects of pharmaceutical compounds that target a given enzyme.
CART. Another interesting finding is the identification of
fragment 28–36 of cocaine- and amphetamine-regulated transcript
(CART), covering part of the amino acid sequence of CART(1–
39). This peptide is involved in regulating many processes
including body weight, reward and endocrine functions [40].
CART is together with NPY believed to regulate the leptin-
mediated feeding response [41].
NPY. Neuropeptide Y is a highly abundant neuropeptide and
a potent neuromodulator involved in several different processes,
e.g. hunger, stress response, cardiovascular function, and circadian
rhythms [42]. Three peptides were identified that span part of the
NPY 1–36 sequence: NPY 1–20, 3–22, and 5–22, none of which
have been previously reported in CSF. It is believed that the intact
NPY 1–36 is the active peptide although it has not been shown in
intact form in CSF.
MOG. From myelin oligodendrocyte glycoprotein (MOG) we
identified six peptides spanning part of the extracellular region
with a common cleavage site C-terminally to the amino acid at
position 81. MOG is found on the surface of the myelin sheath and
has an yet unclear role in multiple sclerosis where autoantibodies
against the protein are found [43]. The levels of autoantibodies
against MOG seem to be an indicator of disease intensity.
Granins. Peptides from the granin family have been
discussed as CSF biomarkers for various diseases such as AD,
multiple sclerosis, schizophrenia, and depression [44]. The granins
(Chromogranin-A (CMGA), Secretogranin-1 (SCG1), Secretogra-
nin-2 (SCG2), Secretogranin-3, 7B2, NESP22, proSAAS, and
VGF) are involved in regulated delivery of several key factors in
CNS such as neurotransmitters, hormones and growth factors.
Peptides from Neurosecretory protein VGF have been associated
with different brain disorders, such as VGF26–62 [45] with
decreased levels in frontotemporal dementia; VGF378–397
[46,47], with decreased levels in AD; VGF23–62 [48], with
increased levels in schizophrenia and in depression; and
SCG2529–566 [48], with decreased levels in depression. In our
study three of the peptides (VGF26–62, VGF23–62, and SCG2529–
566) were found both as intact peptides and in truncated forms,
while the third VGF peptide was only found as peptides exceeding
the sequence length with 1–6 amino acids. In the case of SCG2
and CMGA, an alteration in three peptides is described as
potential marker for multiple sclerosis, decreased SCG1441–493
[49] and SCG1306–365 [49] and increased CMGA194–213 [50,51].
SCG1441–493 has also been found decreased in frontotemporal
dementia [45]. Although we did not identify any of SCG1441–493,
SCG1306–365, or CMGA194–213 as intact peptides, we identified
several forms spanning parts of these sites (Figure 6).
Prion protein. Nine fragments of the prion protein were
identified. The detected peptides are fragments created after the
signal peptide has been removed from the protein with some
starting at amino acid position 23 and others starting more C-
terminally in the octapeptide repeat region which is associated to
prion disease [52]. In CJD, which is characterized by spongiform
degeneration and neuronal death leading to dementia, motor
dysfunction, and eventually death, the prion protein plays a critical
role. When the prion protein assumes an abnormal conformation
it becomes very prone to aggregation, which starts an autocatalytic
cascade that eventually produces neurotoxic species of the protein
[53,54].
Conclusion
Our results show that LC-MALDI MS can be used for
monitoring large numbers of endogenous CSF peptides in sample
volumes relevant to clinical studies. Several of the identified
peptides derive from proteins involved in physiological and
pathological processes in the CNS. The CSF peptidome contains
information about peptides spanning other parts of the proteins
than are found using bottom-up proteomic workflows, and may
thus be a complementary strategy for identifying biomarkers of
disease. Supplementing the method described here with stable
isotope labeling methods for quantification, such as the tandem mass
tag (TMT) or the isobaric tags for relative and absolute quantitation
(iTRAQ) approaches may be a viable strategy for identification of
new biomarkers in CSN disorders.
Methods
Ethics statement
The study was approved by the regional ethics committee at the
University of Gothenburg.
Materials
MALDI grade a-cyano-4-hydroxycinammic acid (HCCA, part
no. 201344) and mass calibrants (Peptide mass calibration
standard II, part no. 222570) were purchased from Bruker
Daltonics. Purified water was used for all solutions (Milli-Q Plus,
Millipore), except for preparation of MALDI matrix solutions,
which were prepared from bottled water (part no. 39253-1L-R)
from Fluka. MWCO filters were purchased from Millipore
(Amicon Ultra 0.5 mL 30 K, part no. UFC503096). FA (98%,
part no. 56302-1061ML-F) was purchased from Fluka, and
Table 1. Cont.
Entry name Protein name
HEG1_HUMAN Isoform 2 of Protein HEG homolog 1
CAD11_HUMAN Isoform 2 of Cadherin-11
CCKN_HUMAN Cholecystokinin preproprotein
B2MG_HUMAN Beta-2-microglobulin precursor
NPY_HUMAN Pro-neuropeptide Y preproprotein
CGRE1_HUMAN Cell growth regulator with EF hand domain protein 1
ALBU_HUMAN Serum albumin preproprotein
doi:10.1371/journal.pone.0042555.t001
CSF Peptidomics by LC-MALDI MS
PLoS ONE | www.plosone.org 7 August 2012 | Volume 7 | Issue 8 | e42555
trifluoro-acetic acid (reagent grade, .98%, part no. T6508) from
Sigma-Aldrich.
CSF samples
CSF samples collected by lumbar puncture from patients
undergoing clinical evaluation were obtained from the Clinical
Neurochemistry Laboratory, Sahlgrenska University Hospital
Mo¨lndal, Sweden. To eliminate cells and other insoluble material,
the CSF samples were centrifuged at 2,0006g at 4uC for 10 min.
Samples were selected from patients who did not display any clear
signs of neurological disorder, with respect to cell counts, albumin
CSF to serum ratio and signs of intrathecal immunoglobulin
production. CSF was de-identified and pooled from 3 different
patients to achieve sufficient volume. All samples were stored at
280uC pending analysis.
Figure 5. Identified endogenous peptides from (a) Amyloid beta A4 protein isoform h precursor (A4_HUMAN, commonly referred
to as APP) and (b) from Amyloid-like protein 1 isoform 1 (APLP1). The peptides identified from A4_HUMAN are all located within the b-
amyloid peptide, starting at or in proximity of the N-terminus of the peptide, defined by the BACE cleavage site. Correspondingly, four of the
peptides identified in APLP1 are generated by BACE cleavage C-terminally to Arg-567.
doi:10.1371/journal.pone.0042555.g005
Figure 4. Comparison of the peptides identified in the current study to other published peptidomic and proteomic data. Only 23% of
the peptides identified in the current study were part of the peptide set reported by Zougman et al. [14]. Comparison of the proteins represented by
the endogenous peptides identified in the current study and in the study by Zougman et al. with the proteins identified in the CSF proteomic analysis
by Schutzer et al. [7] (b) reveals that both peptide sets have a high degree overlap with the proteomic set.
doi:10.1371/journal.pone.0042555.g004
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Sample preparation
The CSF pool was split into aliquots of 500 ml each. To the
samples were added ACN (20%–40% (v/v)) or FA (5%–10% (v/v))
after which the samples were briefly vortexed and incubated for
20 minutes at room temperature. MWCO filters of 10, 30 and
50 kDa were washed with 0.5 ml H2O prior to use. The CSF
samples where centrifuged through the filters according to the
Figure 6. Peptides identified from the Granin family. (a) Chromogranin- A (CMGA), (b) Secretogranin 1 (SCG1), (c) Secretogranin 2 (SCG2), (d)
Neurosecretory protein VGF (VGF).
doi:10.1371/journal.pone.0042555.g006
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manufacturer’s recommendations. The flow-through from the
filters containing the peptide fraction was recovered and lyoph-
ilized. The lyophilized samples were stored at 280uC pending
analysis. To dissolve the samples, 20 ml of 0.5 M HCl, 1% TFA
(v/v) was added and the samples were vortexed for 30 minutes.
Liquid chromatography
Peptides were loaded onto a trap column (Acclaim PepMap100
C18, 75 mm620 mm, LC Packings) and separated with a C18
column (Acclaim PepMap C18, 75 mm6150 mm, LC packings) on
an Ultimate 3000 nano-LC system (Dionex). A sample volume of
20 ml was injected and a 150 minute gradient was used for peptide
separation. The mobile phases used where A, 0.05% TFA (v/v)
and B, 80% ACN (v/v), 0.05% TFA. A solenoid-valve liquid
dispensing robot (Instrument2, M2 Automation) was connected to
the nano-LC device and was used to dispense fraction from the
nano-LC separation onto a 600 mm Anchor Chip 1536 MALDI
sample plate (Bruker Daltonics). The effluent from the nano-LC
was mixed with HCCA matrix solution (4 g/l, 70% ACN (v/v),
0.1% TFA (v/v)) in a T-junction proximally to the capillary end,
and dispensed onto the target plate. Mass calibrants mixed with
HCCA matrix solution (4 g/l in 70% ACN (v/v), 0.1%TFA (v/v))
were deposited in a pattern covering the MALDI target for near-
neighbor external mass calibration.
Mass spectrometry
The fractionated samples were analyzed with a MALDI TOF/
TOF (Ultraflextreme, Bruker Daltonics, Bremen) instrument
operated in the positive ion mode. The analyzed mass range was
700–5,000 Da with deflection up to m/z 600. For MS analysis,
2,000 single shot spectra were accumulated from 10 random
positions on each sample, irradiating each position with 200 laser
pulses. From the MS analysis, compounds with S/N.15, were
selected for MS/MS analysis. For MS/MS analysis 2,000 single
shot spectra were recorded of the precursor ions and 4,000 of the
fragment ions. The analyses of the MS spectra and selection of
compounds for MS/MS analyses was performed using the
WARP-LC software (Bruker Daltonics), which automatically
executed the MS and MS/MS analysis.
Bioinformatics
All the acquired data were processed using the ProteinScape
software (Bruker Daltonics). The MS/MS data were searched
using the Mascot search engine (Matrix science) against the
SwissProt sequence database with the Homo sapiens subset
considering the following variable modifications: phosphorylation,
amidation, deamidation, pyroglutamic acid, oxidation, acetyla-
tion, sulfation, and oxidized as well as reduced cysteines. The error
tolerance for precursor ion masses was set to 15 ppm and for
fragment ion masses, 0.6 Da. All included peptides in the search
were at least 7 amino acids long. A lower peptide score threshold
of 15 was used. Protein hits with at least one peptide with ion score
.27 were retrieved. For these, all peptide matches were manually
validated. The search results were compiled into a protein list
using ProteinScape. All MS/MS spectra considered for protein
identification were manually validated using the BioTools software
(Bruker, Bremen, Germany) according to the following rules: a)
prominent cleavage N-terminally to proline, b) b and y ion pairs, c)
ion series continuity d) major peaks identified as b or y ions e)
resemblance of fragment ion patterns in peptide hits that cover
partially the same amino acid sequence in a protein, f) abundance
of y/b ions according to position of basic amino acids in the
sequence g) abundant cleavage C-terminally to aspartic acid and
glutamic acid if an arginine is present in the sequence.
Comparisons of datasets, protein homology filtering and cellular
localization analysis were performed using the ProteinCenter
software (Thermo Fischer Scientific). In the comparisons with the
HUPO datasets the proteins were clustered using Homogenous
Groups at a 60% level, while the comparisons against Zougman et
al [14] and Schutzer et al [7] were made with clustering for
indistinguishable peptides.
Supporting Information
Table S1 List of identified peptides from the analysis of
the CSF peptidome using LC-MALDI MS/MS.
(XLS)
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